These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
196 related articles for article (PubMed ID: 38761424)
41. Small intestinal bacterial overgrowth in obese patients with biopsy-confirmed metabolic dysfunction-associated steatotic liver disease: a cross-sectional study. Ortiz-López N; Madrid AM; Aleman L; Zazueta A; Smok G; Valenzuela-Pérez L; Poniachik J; Beltrán CJ Front Med (Lausanne); 2024; 11():1376148. PubMed ID: 38854668 [TBL] [Abstract][Full Text] [Related]
42. Metabolic-Dysfunction-Associated Steatotic Liver Disease-Its Pathophysiology, Association with Atherosclerosis and Cardiovascular Disease, and Treatments. Yanai H; Adachi H; Hakoshima M; Iida S; Katsuyama H Int J Mol Sci; 2023 Oct; 24(20):. PubMed ID: 37895151 [TBL] [Abstract][Full Text] [Related]
43. The molecular mechanisms of signaling by cooperative assembly formation in innate immunity pathways. Vajjhala PR; Ve T; Bentham A; Stacey KJ; Kobe B Mol Immunol; 2017 Jun; 86():23-37. PubMed ID: 28249680 [TBL] [Abstract][Full Text] [Related]
44. Severity and Remission of Metabolic Dysfunction-Associated Fatty/Steatotic Liver Disease With Chronic Kidney Disease Occurrence. Gao J; Li Y; Zhang Y; Zhan X; Tian X; Li J; Wang R; He Y; Wang A; Wu S J Am Heart Assoc; 2024 Mar; 13(5):e032604. PubMed ID: 38390843 [TBL] [Abstract][Full Text] [Related]
45. EASL-EASD-EASO Clinical Practice Guidelines on the Management of Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD). ; ; Obes Facts; 2024; 17(4):374-444. PubMed ID: 38852583 [TBL] [Abstract][Full Text] [Related]
46. EASL-EASD-EASO Clinical Practice Guidelines on the management of metabolic dysfunction-associated steatotic liver disease (MASLD). ; ; ; J Hepatol; 2024 Sep; 81(3):492-542. PubMed ID: 38851997 [TBL] [Abstract][Full Text] [Related]
47. Pattern recognition receptors as potential drug targets in inflammatory disorders. McKernan DP Adv Protein Chem Struct Biol; 2020; 119():65-109. PubMed ID: 31997773 [TBL] [Abstract][Full Text] [Related]
48. The "Domino effect" in MASLD: The inflammatory cascade of steatohepatitis. Mladenić K; Lenartić M; Marinović S; Polić B; Wensveen FM Eur J Immunol; 2024 Apr; 54(4):e2149641. PubMed ID: 38314819 [TBL] [Abstract][Full Text] [Related]
54. Innate Immune Sensing of Viruses and Its Consequences for the Central Nervous System. Singh H; Koury J; Kaul M Viruses; 2021 Jan; 13(2):. PubMed ID: 33498715 [TBL] [Abstract][Full Text] [Related]
55. Collaborative action of Toll-like and NOD-like receptors as modulators of the inflammatory response to pathogenic bacteria. Oviedo-Boyso J; Bravo-Patiño A; Baizabal-Aguirre VM Mediators Inflamm; 2014; 2014():432785. PubMed ID: 25525300 [TBL] [Abstract][Full Text] [Related]
56. Recognition of bacterial infection by innate immune sensors. Kumar S; Ingle H; Prasad DV; Kumar H Crit Rev Microbiol; 2013 Aug; 39(3):229-46. PubMed ID: 22866947 [TBL] [Abstract][Full Text] [Related]
57. Updated mechanisms of MASLD pathogenesis. Li Y; Yang P; Ye J; Xu Q; Wu J; Wang Y Lipids Health Dis; 2024 Apr; 23(1):117. PubMed ID: 38649999 [TBL] [Abstract][Full Text] [Related]
58. Application and prospect of targeting innate immune sensors in the treatment of autoimmune diseases. Liu J; Zhang H; Su Y; Zhang B Cell Biosci; 2022 May; 12(1):68. PubMed ID: 35619184 [TBL] [Abstract][Full Text] [Related]
60. Recognition of viruses in the cytoplasm by RLRs and other helicases--how conformational changes, mitochondrial dynamics and ubiquitination control innate immune responses. Ng CS; Kato H; Fujita T Int Immunol; 2012 Dec; 24(12):739-49. PubMed ID: 23087188 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]